Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021 - Key Vendors are F. Hoffmann-La Roche, GE Healthcare, Merck & Novartis - Research and Markets

Research and Markets
Posted on: 28 Nov 17

The "Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021" report has been added to Research and Markets' offering.

The global nanoparticles market in biotechnology and pharmaceutical sectors to grow at a CAGR of 21.72% during the period 2017-2021.

The report covers the present scenario and the growth prospects of the global nanoparticles market in biotechnology and pharmaceutical sectors for 2017-2021. To calculate the market size, the report considers the revenue generated from the retail sales of nanoparticles in the aforesaid sectors. The report also includes a discussion of the key vendors operating in this market.

Nanoparticles are sub-nanosized colloidal structures composed of synthetic or semi-synthetic polymers. These are used in biotechnology and pharmaceutical sectors for studying biological systems for diagnosing diseases and focusing on treatment at the molecular level. The properties of many conventional materials alter when formed from nanoparticles, the reason being nanoparticles have a greater surface area per weight than larger particles, making them more reactive to other molecules

The latest trend gaining momentum in the market is increasing demand for nanoparticles in stem cell therapy. Stem cells have the remarkable potential of developing into different cell types in the body during early life and growth. Stem cells function as an internal repair system that divides to replenish other cells so long the animal or person is alive. Stem cells include embryonic stem cells and non-embryonic adult stem cells that are unspecialized cells. Advancements in stem cell research expose the tremendous potential of stem cells that can change the face of diseases and how we perceive them.

Key vendors

  • F. Hoffmann-La Roche
  • GE Healthcare
  • Merck
  • Novartis

Other prominent vendors

  • AMAG Pharmaceuticals
  • Amgen
  • Bausch & Lomb
  • Biogen
  • Celgene
  • Gilead
  • Ipsen
  • Leadiant Biosciences
  • nanoComposix
  • Pacira Pharmaceuticals
  • Pfizer
  • Shire
  • UCB

Key trends

  • Increasing demand for nanoparticles in stem cell therapy
  • Increasing prevalence of chronic diseases
  • Increasing use of gold nanoparticles

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Market Segmentation By End-User

Part 07: Regional Landscape

Part 08: Decision Framework

Part 09: Drivers And Challenges

Part 10: Market Trends

Part 11: Vendor Landscape

Part 12: Vendor Analysis

Part 13: Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.